Literature DB >> 7871068

Alterations in striatal acetylcholine overflow by cocaine, morphine, and MK-801: relationship to locomotor output.

A Zocchi1, A Pert.   

Abstract

The activity of cholinergic interneurons in the striatum appears to be modulated by a variety of different systems including dopamine, opiate, and glutamate. The purpose of this study was to characterize the effects of drugs known to act on these three systems (i.e., cocaine, morphine, and MK-801) on striatal ACh overflow with microdialysis procedures, and to determine if alterations in ACh function induced by these agents are related to changes in locomotor activity. Cocaine was found to increase striatal ACh following intraperitoneal injections of 20 and 40 mg/kg, but not 10 mg/kg. The increases in locomotor activity induced by cocaine appeared to be dose dependent, while the effects on striatal ACh were not. Injections of 0.1 mg/kg MK-801 (a non-competitive NMDA receptor antagonist) produced dramatic increases in locomotor activity while decreasing striatal ACh overflow. A lower dose (0.03 mg/kg) of MK-801 failed to alter locomotor activity or striatal ACh. Morphine produced an apparent dose-dependent elevation in striatal ACh while only the lowest dose (5 mg/kg) increased locomotor activity. There appears to be no relationship between alterations in striatal ACh and locomotor output following systemic administration of these psychoactive agents.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7871068     DOI: 10.1007/bf02245069

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  65 in total

1.  D1 and D2 dopamine receptor mRNA in rat brain.

Authors:  D M Weiner; A I Levey; R K Sunahara; H B Niznik; B F O'Dowd; P Seeman; M R Brann
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

2.  Regional differences in the regulation of acetylcholine release upon D2 dopamine and N-methyl-D-aspartate receptor activation in rat nucleus accumbens and neostriatum.

Authors:  J M Henselmans; J C Stoof
Journal:  Brain Res       Date:  1991-12-06       Impact factor: 3.252

3.  Influence of noncholinergic drugs on rat striatal acetylcholine levels.

Authors:  P L McGeer; D S Grewaal; E G McGeer
Journal:  Brain Res       Date:  1974-11-15       Impact factor: 3.252

4.  D2 dopamine receptor gene expression by cholinergic neurons in the rat striatum.

Authors:  C Le Moine; F Tison; B Bloch
Journal:  Neurosci Lett       Date:  1990-09-18       Impact factor: 3.046

5.  Increases in striatal acetylcholine by SKF-38393 are mediated through D1 dopamine receptors in striatum and not the frontal cortex.

Authors:  A Zocchi; A Pert
Journal:  Brain Res       Date:  1993-11-12       Impact factor: 3.252

6.  Stimulation of D2-dopamine receptors in rat neostriatum inhibits the release of acetylcholine and dopamine but does not affect the release of gamma-aminobutyric acid, glutamate or serotonin.

Authors:  J C Stoof; T De Boer; P Sminia; A H Mulder
Journal:  Eur J Pharmacol       Date:  1982-10-22       Impact factor: 4.432

7.  Dopamine depletion preferentially impairs D1- over D2-receptor regulation of striatal in vivo acetylcholine release.

Authors:  R Bertorelli; M Zambelli; G Di Chiara; S Consolo
Journal:  J Neurochem       Date:  1992-07       Impact factor: 5.372

8.  Comparison of the role of local anesthetic properties with dopamine uptake blockade in the inhibition of striatal and nucleus accumbens [3H]acetylcholine release by cocaine.

Authors:  A N Gifford; K M Johnson
Journal:  J Pharmacol Exp Ther       Date:  1992-11       Impact factor: 4.030

9.  Independent in vitro regulation by the D-2 dopamine receptor of dopamine-stimulated efflux of cyclic AMP and K+-stimulated release of acetylcholine from rat neostriatum.

Authors:  J C Stoof; J W Kebabian
Journal:  Brain Res       Date:  1982-11-04       Impact factor: 3.252

10.  The effect of naloxone on opioid-induced inhibition and facilitation of acetylcholine release in brain slices.

Authors:  L Beani; C Bianchi; A Siniscalchi
Journal:  Br J Pharmacol       Date:  1982-07       Impact factor: 8.739

View more
  8 in total

1.  CaMKIIα, a modulator of M4 muscarinic acetylcholine receptors.

Authors:  Ming-Lei Guo; Zhenguo Liu; Xiang-Ping Chu; Li-Min Mao; John Q Wang
Journal:  Commun Integr Biol       Date:  2010-09

Review 2.  Cholinergic interneurons in the dorsal and ventral striatum: anatomical and functional considerations in normal and diseased conditions.

Authors:  Kalynda K Gonzales; Yoland Smith
Journal:  Ann N Y Acad Sci       Date:  2015-04-15       Impact factor: 5.691

3.  Inhibition of both alpha7* and beta2* nicotinic acetylcholine receptors is necessary to prevent development of sensitization to cocaine-elicited increases in extracellular dopamine levels in the ventral striatum.

Authors:  Lara Zanetti; Alban de Kerchove D'Exaerde; Alessio Zanardi; Jean-Pierre Changeux; Marina R Picciotto; Michele Zoli
Journal:  Psychopharmacology (Berl)       Date:  2006-06-01       Impact factor: 4.530

4.  CaMKIIalpha interacts with M4 muscarinic receptors to control receptor and psychomotor function.

Authors:  Ming-Lei Guo; Eugene E Fibuch; Xian-Yu Liu; Eun Sang Choe; Shilpa Buch; Li-Min Mao; John Q Wang
Journal:  EMBO J       Date:  2010-05-11       Impact factor: 11.598

Review 5.  The role of acetylcholine in cocaine addiction.

Authors:  Mark J Williams; Bryon Adinoff
Journal:  Neuropsychopharmacology       Date:  2007-10-10       Impact factor: 7.853

Review 6.  Exercise and brain neurotransmission.

Authors:  R Meeusen; K De Meirleir
Journal:  Sports Med       Date:  1995-09       Impact factor: 11.136

7.  Episodic memories and their relevance for psychoactive drug use and addiction.

Authors:  Christian P Müller
Journal:  Front Behav Neurosci       Date:  2013-05-23       Impact factor: 3.558

Review 8.  rTMS-Induced Changes in Glutamatergic and Dopaminergic Systems: Relevance to Cocaine and Methamphetamine Use Disorders.

Authors:  Jessica Moretti; Eugenia Z Poh; Jennifer Rodger
Journal:  Front Neurosci       Date:  2020-03-06       Impact factor: 4.677

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.